Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2018-04-23 Capital/Financing Update
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is a detailed prospectus related to a rights offering, describing the terms of the offering, subscription rights, pricing, and other related information. This type of filing is a capital raising document used to register securities for public sale. It is not an annual report, earnings release, or any other financial report. It is clearly a capital/financing update related to the company's fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2018-04-23 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a reverse stock split and an increase in authorized shares, both approved at the company's Annual Meeting of Stockholders. It also provides voting results for these proposals. The document is not a full financial report but rather an announcement of corporate actions and voting outcomes. Given the detailed voting results and the nature of the content, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4766 characters, which is sufficient to include substantive voting results rather than just a brief announcement. Therefore, the classification is DVA with high confidence.
2018-04-23 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 12, 2018, reporting on the submission of matters to a vote of security holders at the company's 2018 Annual Meeting of Stockholders. It details the voting results on various proposals including election of directors, ratification of auditors, stock option plan increases, and advisory votes on executive compensation. The content is focused on the official results of shareholder votes at the Annual Meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is over 6000 characters and contains detailed vote counts, confirming it is not a mere announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2018-04-17 English
SCHEDULE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A PROXY STATEMENT' and is filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a definitive additional proxy material related to an annual stockholder meeting held on April 12, 2018, with proposals for shareholder voting on corporate matters such as reverse stock split and increase in authorized shares. The content focuses on urging shareholders to vote on these proposals and provides background information on the company and its products. There are no financial statements or detailed financial performance data present. The document is clearly a proxy solicitation material intended to inform and solicit votes from shareholders for the annual meeting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2018-04-16 English
Regulatory Filings 2018
Regulatory Filings
2018-04-06 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes supplemental materials related to the proxy statement for an annual stockholder meeting, specifically discussing tax disclosures related to executive compensation. The presence of detailed compensation and tax deduction information related to executive officers aligns with the definition of Remuneration Information filings. The document is not a full annual report, earnings release, or other financial report, but rather a proxy statement supplement focused on executive compensation disclosures. Therefore, the correct classification is DEF 14A (Remuneration Information). The document length and content support a high confidence in this classification.
2018-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.